# Agios Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/agios-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Cambridge, US
- Website: www.agios.com
- Total disclosed funding: $120M
- Latest round: Series C (Nov 17, 2011)
- Investors on record: 5

## About

Agios Pharmaceuticals, Inc. is a biotechnology company dedicated to developing innovative therapies for rare diseases, focusing on cellular metabolism and specialized treatments for hemolytic anemia.Founded in 2007 and headquartered in Cambridge, US, Agios Pharmaceuticals focuses on advancing therapies for rare diseases. The company has undergone significant changes, such as the acquisition of its oncology business by Les Laboratories Servier for USD 1.8 billion, which was finalized in April 2021. The company has attracted substantial investment over the years, with the most recent funding round being a TRADE SALE, raising USD 1,800 mn. Brian Goff and Jackie Fouse currently serve as CEOs.Agios Pharmaceuticals specializes in pioneering therapies for rare diseases, particularly in cellular metabolism. Its primary product, PYRUKYND® (mitapivat), is approved for adults with pyruvate kinase deficiency, a rare form of hemolytic anemia. The company is also developing AG-946, an investigational PK activator, targeting various hemolytic anemias. Agios serves healthcare providers, hospitals, and specialty pharmacies in North America, Europe, and parts of Asia.In 2024, Agios Pharmaceuticals reported a revenue of USD 36.50 mn, stemming primarily from its flagship product, PYRUKYND®. The company generates revenue through partnerships with healthcare providers and specialty pharmacies that facilitate access to its therapies. However, it reported an EBITDA loss of USD 420.08 mn for the same year.Agios Pharmaceuticals is focused on launching additional products and expanding its market presence. Following its recent acquisition, the company aims to enhance its offerings in malignant hematology and potentially enter the solid tumor market. The funding obtained from the TRADE SALE and previous rounds will facilitate these initiatives, aligning with its strategic direction to broaden therapeutic options for patients with rare diseases.

## Funding rounds

- Series C, Nov 17, 2011, $78M — ARCH Venture Partners, Flagship Pioneering, Third Rock Ventures, Celgene
- Series B, Apr 16, 2010, $8.8M — ARCH Venture Partners, Flagship Pioneering, Third Rock Ventures, Celgene
- Series A, Aug 21, 2009, $18M — ARCH Venture Partners, Third Rock Ventures, Accelerate Brain Cancer Cure
- Series A, Jun 20, 2008, $15M — ARCH Venture Partners, Flagship Pioneering, Third Rock Ventures
- Seed, Jun 1, 2007 — ARCH Venture Partners, Flagship Pioneering

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Seed, Series A, Series B, Series C
- Flagship Pioneering (https://capitalatlas.ai/funds/flagship-pioneering) — Seed, Series A, Series B, Series C
- Third Rock Ventures (https://capitalatlas.ai/funds/third-rock-ventures) — Series A, Series B, Series C
- Accelerate Brain Cancer Cure — Series A
- Celgene — Series B, Series C